Eledon Pharmaceuticals is a clinical stage biopharmaceutical company specializing in developing medications for patients with autoimmune diseases and those in need of organ or cell-based transplants. Their primary product candidate, AT-1501, is currently undergoing Phase 2a and Phase 2 clinical trials for the treatment of ALS and type 1 diabetes respectively. The company, previously known as Novus Therapeutics, is based in Irvine, California.